Axogen's Ownership Structure: Institutional Dominance and Insider Sales

Axogen, Inc. is heavily dominated by institutional owners with 88% ownership. This suggests that the stock price may be vulnerable to their trading decisions. A total of 12 investors have a majority stake in the company with 52% ownership. However, hedge funds do not have a significant presence in Axogen.

AxoGen, Inc. (NASDAQ: AXGN) has seen a significant shift in institutional ownership, with 88% of the company's stock now held by institutional investors. This high level of institutional ownership suggests that the stock price may be sensitive to the trading decisions of these large shareholders [1].

A total of 12 investors, including Quantbot Technologies LP, Wyoming State, Fifth Third Bancorp, GAMMA Investing LLC, Zurcher Kantonalbank Zurich Cantonalbank, and KLP Kapitalforvaltning AS, hold a majority stake in the company, accounting for 52% of the shares. However, hedge funds do not have a significant presence in AxoGen, with only 81 institutional investors adding shares to their portfolios and 102 decreasing their positions in the most recent quarter [2].

Quantbot Technologies LP, for instance, recently purchased 34,182 shares valued at approximately $632,000, bringing its ownership to 0.08% of AxoGen. This acquisition follows a series of strategic moves by other institutional investors who have either increased their stakes or initiated new positions in the company [1].

The recent SEC filings also indicate that several other institutional investors have made notable changes to their positions in AxoGen. Wyoming State bought a new position valued at $31,000 during the fourth quarter, while Fifth Third Bancorp acquired a new stake valued at $92,000 during the first quarter. GAMMA Investing LLC raised its holdings by 3,884.6% during the first quarter, owning 5,698 shares valued at $105,000 after buying an additional 5,555 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank and KLP Kapitalforvaltning AS also initiated new stakes valued at $146,000 and $150,000, respectively [1].

The high level of institutional ownership in AxoGen suggests that the stock price may be influenced by the collective actions of these large shareholders. However, the absence of a significant hedge fund presence may provide some stability to the stock price, as hedge funds are often seen as more aggressive traders.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-quantbot-technologies-lp-purchases-new-shares-in-axogen-inc-axgn-2025-08-26/
[2] https://www.quiverquant.com/news/Axogen%2C+Inc.+Receives+FDA+Extension+for+Avance%C2%AE+Nerve+Graft+Biologics+License+Application+Review